1.Integrative analysis of transcriptome, DNA methylome, and chromatin accessibility reveals candidate therapeutic targets in hypertrophic cardiomyopathy.
Junpeng GAO ; Mengya LIU ; Minjie LU ; Yuxuan ZHENG ; Yan WANG ; Jingwei YANG ; Xiaohui XUE ; Yun LIU ; Fuchou TANG ; Shuiyun WANG ; Lei SONG ; Lu WEN ; Jizheng WANG
Protein & Cell 2024;15(11):796-817
Hypertrophic cardiomyopathy (HCM) is the most common inherited heart disease and is characterized by primary left ventricular hypertrophy usually caused by mutations in sarcomere genes. The mechanism underlying cardiac remodeling in HCM remains incompletely understood. An investigation of HCM through integrative analysis at multi-omics levels will be helpful for treating HCM. DNA methylation and chromatin accessibility, as well as gene expression, were assessed by nucleosome occupancy and methylome sequencing (NOMe-seq) and RNA-seq, respectively, using the cardiac tissues of HCM patients. Compared with those of the controls, the transcriptome, DNA methylome, and chromatin accessibility of the HCM myocardium showed multifaceted differences. At the transcriptome level, HCM hearts returned to the fetal gene program through decreased sarcomeric and metabolic gene expression and increased extracellular matrix gene expression. In the DNA methylome, hypermethylated and hypomethylated differentially methylated regions were identified in HCM. At the chromatin accessibility level, HCM hearts showed changes in different genome elements. Several transcription factors, including SP1 and EGR1, exhibited a fetal-like pattern of binding motifs in nucleosome-depleted regions in HCM. In particular, the inhibition of SP1 or EGR1 in an HCM mouse model harboring sarcomere mutations markedly alleviated the HCM phenotype of the mutant mice and reversed fetal gene reprogramming. Overall, this study not only provides a high-precision multi-omics map of HCM heart tissue but also sheds light on the therapeutic strategy by intervening in the fetal gene reprogramming in HCM.
Cardiomyopathy, Hypertrophic/metabolism*
;
Humans
;
Animals
;
DNA Methylation
;
Mice
;
Transcriptome
;
Chromatin/genetics*
;
Early Growth Response Protein 1/metabolism*
;
Male
;
Epigenome
;
Nucleosomes/genetics*
;
Female
;
Middle Aged
;
Disease Models, Animal
;
Adult
2.Total triterpenoids from Ganoderma Lucidum suppresses prostate cancer cell growth by inducing growth arrest and apoptosis.
Tao WANG ; Zi-ping XIE ; Zhan-sen HUANG ; Hao LI ; An-yang WEI ; Jin-ming DI ; Heng-jun XIAO ; Zhi-gang ZHANG ; Liu-hong CAI ; Xin TAO ; Tao QI ; Di-ling CHEN ; Jun CHEN
Journal of Huazhong University of Science and Technology (Medical Sciences) 2015;35(5):736-741
In this study, one immortalized human normal prostatic epithelial cell line (BPH) and four human prostate cancer cell lines (LNCaP, 22Rv1, PC-3, and DU-145) were treated with Ganoderma Lucidum triterpenoids (GLT) at different doses and for different time periods. Cell viability, apoptosis, and cell cycle were analyzed using flow cytometry and chemical assays. Gene expression and binding to DNA were assessed using real-time PCR and Western blotting. It was found that GLT dose-dependently inhibited prostate cancer cell growth through induction of apoptosis and cell cycle arrest at G1 phase. GLT-induced apoptosis was due to activation of Caspases-9 and -3 and turning on the downstream apoptotic events. GLT-induced cell cycle arrest (mainly G1 arrest) was due to up-regulation of p21 expression at the early time and down-regulation of cyclin-dependent kinase 4 (CDK4) and E2F1 expression at the late time. These findings demonstrate that GLT suppresses prostate cancer cell growth by inducing growth arrest and apoptosis, which might suggest that GLT or Ganoderma Lucidum could be used as a potential therapeutic drug for prostate cancer.
Antineoplastic Agents, Phytogenic
;
isolation & purification
;
pharmacology
;
Apoptosis
;
drug effects
;
Caspase 3
;
genetics
;
metabolism
;
Caspase 9
;
genetics
;
metabolism
;
Cell Line, Tumor
;
Cell Survival
;
drug effects
;
Cyclin D1
;
genetics
;
metabolism
;
Cyclin-Dependent Kinase 4
;
genetics
;
metabolism
;
Cyclin-Dependent Kinase Inhibitor p21
;
genetics
;
metabolism
;
Dose-Response Relationship, Drug
;
E2F1 Transcription Factor
;
genetics
;
metabolism
;
G1 Phase Cell Cycle Checkpoints
;
drug effects
;
genetics
;
Gene Expression Regulation, Neoplastic
;
Humans
;
Male
;
Nucleosomes
;
drug effects
;
metabolism
;
pathology
;
Plant Extracts
;
chemistry
;
Prostate
;
drug effects
;
metabolism
;
pathology
;
Reishi
;
chemistry
;
Signal Transduction
;
Triterpenes
;
isolation & purification
;
pharmacology
3.Nucleosome assembly and epigenetic inheritance.
Protein & Cell 2010;1(9):820-829
In eukaryotic cells, histones are packaged into octameric core particles with DNA wrapping around to form nucleosomes, which are the basic units of chromatin (Kornberg and Thomas, 1974). Multicellular organisms utilise chromatin marks to translate one single genome into hundreds of epigenomes for their corresponding cell types. Inheritance of epigenetic status is critical for the maintenance of gene expression profile during mitotic cell divisions (Allis et al., 2006). During S phase, canonical histones are deposited onto DNA in a replication-coupled manner (Allis et al., 2006). To understand how dividing cells overcome the dilution of epigenetic marks after chromatin duplication, DNA replication coupled (RC) nucleosome assembly has been of great interest. In this review, we focus on the potential influence of RC nucleosome assembly processes on the maintenance of epigenetic status.
Animals
;
Chromatin Assembly and Disassembly
;
genetics
;
physiology
;
DNA Replication
;
Epigenesis, Genetic
;
Histones
;
chemistry
;
physiology
;
Humans
;
Nucleosomes
;
genetics
;
physiology
;
Protein Structure, Quaternary

Result Analysis
Print
Save
E-mail